Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Claus Garbe, Ana-Maria Forsea, Teresa Amaral, Petr Arenberger, Philippe Autier, Marianne Berwick, Brigitta Boonen, Matilda Bylaite, Veronique Del Marmol, Brigitte Dreno, Maria Concetta Fargnoli, Alan C Geller, Adele C Green, Rüdiger Greinert, Axel Hauschild, Catherine A Harwood, Isabelle Hoorens, Lidija Kandolf, Roland Kaufmann, Nicole Kelleners-Smeets, Aimilios Lallas, Celeste Lebbé, Ulrike Leiter, Henry W Lim, Caterina Longo, Joseph Malvehy, David Moreno, Giovanni Pellacani, Ketty Peris, Caroline Robert, Philippe Saiag, Dirk Schadendorf, H Peter Soyer, Eggert Stockfleth, Alex Stratigos, Hisashi Uhara, Ricardo Vieira, Beate Volkmer, Martin A Weinstock, Dagmar Whitaker, Iris Zalaudek, David C Whiteman, Lieve Brochez
Cancers of the skin are the most commonly occurring cancers in humans. In fair-skinned populations, up to 95% of keratinocyte skin cancers and 70-95% of cutaneous melanomas are caused by ultraviolet radiation and are thus theoretically preventable. Currently, however, there is no comprehensive global advice on practical steps to be taken to reduce the toll of skin cancer. To address this gap, an expert working group comprising clinicians and researchers from Africa, America, Asia, Australia, and Europe, together with learned societies (European Association of Dermato-Oncology, Euromelanoma, Euroskin, European Union of Medical Specialists, and the Melanoma World Society) reviewed the extant evidence and issued the following evidence-based recommendations for photoprotection as a strategy to prevent skin cancer...
April 24, 2024: European Journal of Cancer
#2
JOURNAL ARTICLE
Mutlay Sayan, Ming-Hui Chen, Marian Loffredo, Elizabeth McMahon, Shalini Moningi, Peter F Orio, Paul L Nguyen, Anthony V D'Amico
PURPOSE: Although a contemporary randomized clinical trial has led to the use of whole-pelvic radiation therapy (WPRT), long-term data evaluating a potential reduction in mortality are lacking and are addressed in the current study. MATERIALS AND METHODS: From 2005 to 2015, 350 men with localized, unfavorable-risk prostate cancer (PC) were randomly assigned to receive androgen deprivation therapy (ADT) and RT plus docetaxel versus ADT and RT. Treatment of the pelvic lymph nodes was at the discretion of the treating physician...
May 1, 2024: Journal of Clinical Oncology
#3
JOURNAL ARTICLE
Erin E Watson E, Katrina Hueniken, Junhyung Lee, Shao Hui Huang, Amr El Maghrabi, Wei Xu, Amy C Moreno, C Jillian Tsai, Ezra Hahn, Andrew J McPartlin, Christopher M K L Yao, David P Goldstein, John R De Almeida, John N Waldon, Clifton D Fuller, Andrew J Hope, Salvatore L Ruggiero, Michael Glogauer, Ali A Hosni
PURPOSE: Osteoradionecrosis of the jaw (ORN) can manifest in varying severity. The aim of this study is to identify ORN risk factors and develop a novel classification to depict the severity of ORN. METHODS: Consecutive patients with head and neck cancer (HNC) treated with curative-intent intensity-modulated radiation therapy (IMRT) (≥45 Gy) from 2011 to 2017 were included. Occurrence of ORN was identified from in-house prospective dental and clinical databases and charts...
May 1, 2024: Journal of Clinical Oncology
#4
JOURNAL ARTICLE
Douglas E Peterson, Shlomo A Koyfman, Noam Yarom, Charlotte Duch Lynggaard, Nofisat Ismaila, Lone E Forner, Clifton David Fuller, Yvonne M Mowery, Barbara A Murphy, Erin Watson, David H Yang, Ivan Alajbeg, Paolo Bossi, Michael Fritz, Neal D Futran, Daphna Y Gelblum, Edward King, Salvatore Ruggiero, Derek K Smith, Alessandro Villa, Jonn S Wu, Deborah Saunders
PURPOSE: To provide evidence-based recommendations for prevention and management of osteoradionecrosis (ORN) of the jaw secondary to head and neck radiation therapy in patients with cancer. METHODS: The International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library databases were searched for randomized controlled trials and observational studies, published between January 1, 2009, and December 1, 2023...
May 1, 2024: Journal of Clinical Oncology
#5
JOURNAL ARTICLE
Deborah Saunders, Shlomo A Koyfman, Nofisat Ismaila, Neal D Futran, Yvonne M Mowery, Erin Watson, David H Yang, Douglas E Peterson
No abstract text is available yet for this article.
May 1, 2024: JCO oncology practice
#6
JOURNAL ARTICLE
Jacqueline A Shaw, Karen Page, Evie Wren, Elza C de Bruin, Ekaterina Kalashnikova, Robert Hastings, Rob McEwen, Eddie Zhang, Marc Wadsley, Emmanuel Acheampong, Derek Renner, Kelly L T Gleason, Bana Ambasager, Daniel Stetson, Daniel Fernandez-Garcia, David Guttery, Rebecca C Allsopp, Angel Rodriguez, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Minetta C Liu, Cathy Richards, Justin Stebbing, Simak Ali, Farah Rehman, Susan Cleator, Laura Kenny, Samreen Ahmed, Anne C Armstrong, R Charles Coombes
PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data...
April 2024: JCO Precision Oncology
#7
JOURNAL ARTICLE
Kathryn R Tringale, Anna Skakodub, Jacklynn Egger, Jordan Eichholz, Yao Yu, Daniel Gomez, Andreas Rimner, Bob Li, Yoshiya Yamada, Jessica Wilcox, Nelson Moss, Brandon S Imber, Natasha Rekhtman, Marina K Baine, Charles M Rudin, Luke R G Pike
PURPOSE: Small cell lung cancer (SCLC) often metastasizes to the brain and has poor prognosis. SCLC subtypes distinguished by expressing transcriptional factors ASCL1 or NEUROD1 have been identified. This study investigates the impact of transcription factor-defined SCLC subtype on incidence and outcomes of brain metastases (BMs). METHODS: Patients with SCLC with ASCL1 (A) and NEUROD1 (N) immunohistochemical expression status were identified and classified: (1) A+/N-, (2) A+/N+, (3) A-/N+, and (4) A-/N-...
April 2024: JCO Precision Oncology
#8
JOURNAL ARTICLE
Nicole Yeung, Tiffany Li, Hui-Ming Lin, Hannah C Timmins, David Goldstein, Michelle Harrison, Michael Friedlander, Kate L Mahon, Corey Giles, Peter J Meikle, Susanna B Park, Lisa G Horvath
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of cytotoxic cancer treatment, often necessitating dose reduction (DR) or chemotherapy discontinuation (CD). Studies on peripheral neuropathy related to chemotherapy, obesity, and diabetes have implicated lipid metabolism. This study examined the association between circulating lipids and CIPN. METHODS: Lipidomic analysis was performed on plasma samples from 137 patients receiving taxane-based treatment...
April 2024: JCO Precision Oncology
#9
JOURNAL ARTICLE
Andrew T Lenis, Karissa Whiting, Vignesh Ravichandran, Jacob E Tallman, Syed M Alam, Carissa E Chu, Manual De Jesus Escano, Emily Bochner, Andrew Katims, Peter A Reisz, Hong Truong, Timothy N Clinton, Leon Telis, Shawn Dason, Victor McPherson, Min Yuen Teo, Samuel Funt, David Aggen, Alvin C Goh, Timothy F Donahue, Eugene K Cha, S Machele Donat, Harry W Herr, Guido Dalbagni, Nikolaus Schultz, Michael F Berger, Dean F Bajorin, Jonathan E Rosenberg, Bernard H Bochner, Irina Ostrovnaya, Hikmat Al-Ahmadie, David B Solit, Gopa Iyer, Eugene J Pietzak
PURPOSE: Patients with residual invasive bladder cancer after neoadjuvant chemotherapy (NAC) and radical cystectomy have a poor prognosis. Data on adjuvant therapy for these patients are conflicting. We sought to evaluate the natural history and genomic landscape of chemotherapy-resistant bladder cancer to inform patient management and clinical trials. METHODS: Data were collected on patients with clinically localized muscle-invasive urothelial bladder cancer treated with NAC and cystectomy at our institution between May 15, 2001, and August 15, 2019, and completed four cycles of gemcitabine and cisplatin NAC, excluding those treated with adjuvant therapies...
April 2024: JCO Precision Oncology
#10
JOURNAL ARTICLE
James H Stoeckle, Sarah G Poland, Hannah Maynard, Stefanie D Roman, Daniel Mettman, Danil V Makarov, Scott Sherman, Daniel J Becker
PURPOSE: Previous studies document underuse of next-generation sequencing (NGS). We examined the impact to oncology care for veterans of incorporating NGS ordering into the Veterans Affairs (VA) electronic medical record (EMR) at two New York City VA Medical Centers. METHODS: We identified patients with non-small cell lung cancer and prostate cancer with oncology clinic visits and NGS testing indications between January and December 2021. Patients were divided into external ordering (EO) with visits before we implemented an EMR ordering system for NGS in July 2021, and internal ordering (IO) with visits after this date...
April 2024: JCO Precision Oncology
#11
JOURNAL ARTICLE
Eiichi Nakao, Michitaka Honda, Noriyuki Uesugi, Mitsumasa Osakabe, Ayaka Sato, Yukitoshi Todate, Mizunori Yaegashi, Yoshinao Takano, Akira Sasaki, Koji Kono, Tamotsu Sugai
BACKGROUND: The prognostic value of the pathological response to preoperative chemoradiotherapy (CRT) in rectal cancer (RC) remains unknown. OBJECTIVES: We aimed to assess the predictive value of the response to CRT that was derived from an evaluation of the histological findings (whole-section vs. representative-section sampling) and attempted to determine an objective cut-off value for the tumor regression grade (TRG). METHODS: We examined the association of the TRG with the outcomes (recurrence-free survival [RFS] and overall survival [OS]) of 78 patients with RC...
May 1, 2024: Journal of Surgical Oncology
#12
JOURNAL ARTICLE
Venu Thatikonda, Verena Supper, Johannes Wachter, Onur Kaya, Anju Kombara, Ceren Bilgilier, Madhwesh C Ravichandran, Jesse J Lipp, Rahul Sharma, Lukas Badertscher, Andrew S Boghossian, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Sarah Grosche, Ralph A Neumüller, Barbara Mair, Federico Mauri, Alexandra Popa
Transcription factors (TFs) are important mediators of aberrant transcriptional programs in cancer cells. In this study, we focus on TF activity (TFa) as a biomarker for cell-line-selective anti-proliferative effects, in that high TFa predicts sensitivity to loss of function of a given gene (i.e., genetic dependencies [GDs]). Our linear-regression-based framework identifies 3,047 pan-cancer and 3,952 cancer-type-specific candidate TFa-GD associations from cell line data, which are then cross-examined for impact on survival in patient cohorts...
April 30, 2024: Cell Reports
#13
JOURNAL ARTICLE
Hannah Kang Moran, Lori Spoozak, Joanna Veazey Brooks
This study aimed to elucidate the relationship between mentorship, survivorship, and identity construction in people who have had gynecologic cancer and participated as mentors in a peer mentorship program. A qualitative descriptive study was designed, and hour-long semi-structured interviews with peer mentors were conducted. Interviews investigated how serving as a peer mentor influenced understanding of mentors' own cancer experiences. Thematic analysis was then conducted. All authors open-coded a subset of interviews to develop a codebook, which was then used to code the remaining transcripts...
May 1, 2024: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
#14
JOURNAL ARTICLE
Yoshinori Kagawa, Chaochen Wang, Yongzhe Piao, Long Jin, Yoshinori Tanizawa, Zhihong Cai, Yu Sunakawa
BACKGROUND: Oxaliplatin-containing adjuvant regimens (folinic acid, fluorouracil, and oxaliplatin/capecitabine and oxaliplatin [FOLFOX/CAPOX]) are used after curative resection of colorectal cancer (CRC). However, real-world evidence regarding treatment sequences and outcomes in patients with early recurrence CRC after adjuvant chemotherapy is limited. OBJECTIVE: We aimed to describe the patient characteristics, treatment sequence, and overall duration of second-line (2L) therapy in patients with early recurrence CRC who received adjuvant chemotherapy (FOLFOX/CAPOX) followed by folinic acid, fluorouracil, and irinotecan (FOLFIRI) + anti-angiogenesis drugs (AA) or FOLFIRI + anti-epidermal growth factor receptor (EGFR) antibodies...
May 1, 2024: Targeted Oncology
#15
JOURNAL ARTICLE
Margherita Rimini, Gianluca Masi, Sara Lonardi, Federico Nichetti, Tiziana Pressiani, Daniele Lavacchi, Lucchetti Jessica, Guido Giordano, Mario Scartozzi, Emiliano Tamburini, Alessandro Pastorino, Ilario Giovanni Rapposelli, Bruno Daniele, Erika Martinelli, Ingrid Garajova, Giuseppe Aprile, Marta Schirripa, Vincenzo Formica, Francesca Salani, Costanza Winchler, Francesca Bergamo, Rita Balsano, Eleonora Gusmaroli, Angotti Lorenzo, Matteo Landriscina, Andrea Pretta, Ilaria Toma, Chiara Pirrone, Anna Diana, Francesco Leone, Oronzo Brunetti, Giovanni Brandi, Silvio Ken Garattini, Maria Antonietta Satolli, Federico Rossari, Lorenzo Fornaro, Monica Niger, Valentina Zanuso, Antonio De Rosa, Francesca Ratti, Luca Aldrighetti, Filippo De Braud, Silvia Foti, Mario Domenico Rizzato, Caterina Vivaldi, Cascinu Stefano, Lorenza Rimassa, Lorenzo Antonuzzo, Andrea Casadei-Gardini
BACKGROUND: The TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed cell death ligand 1 (anti-PD-L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). OBJECTIVE: The present study investigated for the first time the impact on survival of adding durvalumab to cisplatin/gemcitabine compared with cisplatin/gemcitabine in a real-world setting. PATIENTS AND METHODS: The analyzed population included patients with unresectable, locally advanced, or metastatic BTC treated with durvalumab in combination with cisplatin/gemcitabine or with cisplatin/gemcitabine alone...
May 1, 2024: Targeted Oncology
#16
JOURNAL ARTICLE
Yuan Li, Weili Zhang, Jie Du, Jinlong Hu, Ruixi Hu, Ziyang Zeng, E-Er-Man-Bie-Ke Jin-Si-Han, Shaopu Lian, Hao Wang, Yunfeng Li, Zhizhong Pan, Cheng Feng, Xuan Zhang, Zhenhai Lu
BACKGROUND: Neoadjuvant immunotherapy with programmed death-ligand 1 blockade for colon cancer, especially for mismatch repair-deficient (dMMR)/high microsatellite instability (MSI-H) colon cancer, has gained considerable attention recently. OBJECTIVE: This study aimed to assess the safety and efficacy of neoadjuvant subcutaneous envafolimab in patients with dMMR/MSI-H locally advanced colon cancer. METHODS: Patients with dMMR/MSI-H locally advanced colon cancer treated with envafolimab at Sun Yat-sen University Cancer Center and Yunnan Cancer Hospital from October 2021 to July 2023 were retrospectively reviewed and analyzed...
April 30, 2024: Targeted Oncology
#17
REVIEW
Roganie Govender, Nicky Gilbody, Gavriella Simson, Rhiannon Haag, Ceri Robertson, Emma Stuart
Dysphagia, difficulty in eating and drinking, remains the most common side effect of radiotherapy treatment for head and neck cancer (HNC) with devastating consequences for function and quality of life (QOL). Over the past decade, 5-year survival has improved due to multiple factors including treatment advances, reduction in smoking, introduction of the human papillomavirus (HPV) vaccine and more favourable prognosis of HPV-related cancers. Increased prevalence of HPV-positive disease, which tends to affect younger individuals, has led to an elevated number of people living for longer with the sequelae of cancer and its treatment...
May 1, 2024: Current Treatment Options in Oncology
#18
JOURNAL ARTICLE
Bin Chen, Yi Liu, Yuping He, Chenfu Shen
BACKGROUND: Interleukin-4 inducible gene 1 (IL4I1) regulates tumor progression in numerous tumor types. However, its correlation with immune infiltration and prognosis of patients in a pan-cancer setting remains unclear. METHODS: Data from the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), UALCAN, Clinical Proteomic Tumor Analysis Consortium (CPTAC), Gene Expression Omnibus (GEO), cBioPortal, Cancer Single-cell State Atlas (CancerSEA), and Tumor IMmune Estimation Resource(TIMER) databases were used to evaluate IL4I1 expression, clinical features and prognostic effects, gene set enrichment, and correlation with immune cell infiltration, as well as the relationship between IL4I1 methylation and expression and survival prognosis...
May 1, 2024: Discover. Oncology
#19
JOURNAL ARTICLE
Julia N Shanno, Abigail E Daly, Kyle J Anderman, Heidi S Santa Cruz, Alexandra J Webster, Robert M Pride, Michelle C Specht, Michele A Gadd, Tawakalitu O Oseni, Francys C Verdial, Tolga Ozmen, Rebecca Kwait, Amy S Colwell, Barbara L Smith
BACKGROUND: Nipple-sparing mastectomy (NSM) is an oncologically safe approach for breast cancer treatment and prevention; however, there are little long-term data to guide management for patients whose nipple margins contain tumor or atypia. METHODS: NSM patients with tumor or atypia in their nipple margin were identified from a prospectively maintained, single-institution database of consecutive NSMs. Patient and tumor characteristics, treatment, recurrence, and survival data were assessed...
May 1, 2024: Annals of Surgical Oncology
#20
REVIEW
Simin Ye, Shiyu Chen, Xiaoyan Yang, Xiaoyong Lei
Breast cancer (BC) ranks first among female malignant tumors and involves hormonal changes and genetic as well as environmental risk factors. In recent years, with the improvement of medical treatment, a variety of therapeutic approaches for breast cancer have emerged and have strengthened to accommodate molecular diversity. However, the primary way to improve the effective treatment of breast cancer patients is to overcome treatment resistance. Recent studies have provided insights into the mechanisms of resistance to exosome effects in BC...
May 1, 2024: Discover. Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
